Product Information
VALGANCICLOVIR HCL 50 MG/ML is a generic product labeled by Aurobindo Pharma Limited, priced at $1.0058 per ML under NDC 59651044401. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Nov 17, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50 mg/mL
Manufacturer
Aurobindo Pharma LimitedNDC
59651044401
Classification
Generic
Dosage Form
FOR SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VALGANCICLOVIR HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215124FDA Approved
11/17/2022
TE Code
AB
On Market Since
11/17/2022
Pharmacological Classes
Price Statistics
The NADAC for VALGANCICLOVIR HCL 50 MG/ML has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 70.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0058 per ML |
|---|---|
| All-time high | $3.4521 (May 15, 2024) |
| All-time low | $0.9898 (Aug 19, 2026) |
| 52-week high | $1.4406 |
| 52-week low | $0.9898 |
| Median price | $1.9639 |
| Average price | $1.9039 |
| Largest weekly change | -21.0% (Oct 23, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Valganciclovir hydrochloride powder, market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Valganciclovir hydrochloride powder, market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VALGANCICLOVIR HCL 50 MG/ML?
The current National Average Drug Acquisition Cost (NADAC) for VALGANCICLOVIR HCL 50 MG/ML, manufactured by Aurobindo Pharma Limited, is $1.0058 per ML (NDC 59651044401), effective Sep 30, 2026.
How has the price of VALGANCICLOVIR HCL 50 MG/ML changed over time?
Over the history we have for it, the NADAC for VALGANCICLOVIR HCL 50 MG/ML has declined 70.9%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for VALGANCICLOVIR HCL 50 MG/ML?
Since Apr 17, 2024, the NADAC for VALGANCICLOVIR HCL 50 MG/ML has ranged from a low of $0.9898 (Aug 19, 2026) to a high of $3.4521 (May 15, 2024), with a median of $1.9639 per ML.
Are there cheaper alternatives to VALGANCICLOVIR HCL 50 MG/ML?
No other NADAC-published product currently shares the active ingredient and strength of VALGANCICLOVIR HCL 50 MG/ML in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VALGANCICLOVIR HCL 50 MG/ML?
VALGANCICLOVIR HCL 50 MG/ML (NDC 59651044401) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.